MarketLens
Sign Up

What Do Recent Insider Sales at Spyre Therapeutics Signal

5 months ago
SHARE THIS ON:

What Do Recent Insider Sales at Spyre Therapeutics Signal

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News2 weeks ago

Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?

Spyre's investment case hinges on upcoming clinical readouts, as its broad pipeline and cash runway clash with an elevated valuation that leaves limited room for error.
Stock News2 months ago

Kymera's CEO Sold $6 Million in Stock After a 170% Run

Kymera CEO sold ~$6M in stock after a 170% run, exercising 50,000 shares at $119 on July 7. The sale reduced direct holdings by 7%.
Stock News2 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics granted stock options for 58,843 shares and 2,134 RSUs to six non-executive employees as inducement awards, approved July 1, 2026, to secure their employment.

Breaking News

View All →

Top Headlines

View More →
Stock News58 minutes ago

Nvidia in talks to invest in Anthropic's mega IPO, sources say

Stock News1 hour ago

Alphabet (GOOGL) Beats Stock Market Upswing: What Investors Need to Know

Stock News1 hour ago

Alphabet Inc. (GOOG) Outperforms Broader Market: What You Need to Know

Stock News1 hour ago

Apple (AAPL) Rises Higher Than Market: Key Facts

Stock News1 hour ago

Oracle: The $28B CapEx Illusion And The Reality Of Software Cannibalization